Patents Assigned to Ergo Science Incorporated
-
Patent number: 5905083Abstract: Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems, such as rheumatoid arthritis. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.Type: GrantFiled: June 2, 1995Date of Patent: May 18, 1999Assignee: Ergo Science IncorporatedInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5714519Abstract: This invention relates to a method for modifying metabolism in a vertebrate animal which entails the administration of pantethine or cysteamine at a predetermined time daily. The method is useful in the treatment of hyperglycemia, glucose intolerance, insulin resistance, and hyperinsulinemia.Type: GrantFiled: June 7, 1995Date of Patent: February 3, 1998Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5700800Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: October 31, 1995Date of Patent: December 23, 1997Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5688794Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of non-insulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, or a prolactin stimulating compound.Type: GrantFiled: October 31, 1995Date of Patent: November 18, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5679685Abstract: Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90% in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37 C and is useful for adjusting the plasma prolactin profile of a patient.Type: GrantFiled: June 2, 1995Date of Patent: October 21, 1997Assignees: Ergo Science, Incorporated, Geneva Pharmaceuticals, Inc.Inventors: Anthony H. Cincotta, Manuel Cincotta, Jr., Christopher Louis Pelloni, Christopher Eric Runice, Sandra Louise Tigner
-
Patent number: 5654313Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 6, 1995Date of Patent: August 5, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5635512Abstract: A process for the long term modification and regulation of linid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 5, 1995Date of Patent: June 3, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana Business and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5626860Abstract: Disclosed herein are methods for regulating or ameliorating lipid and glucose metabolism and reducing in a vertebrate animal body fat stores, insulin resistance, hyperinsulinemia, hyperglycemia, hyperlipidemia, elevated blood lipoproteins (such as triglycerides and cholesterol including chylomicrons, VLDL and LDL) and/or increasing in the subject the plasma HDL. The methods comprise administration or timed administration of inhibitors of dopamine beta hydroxylase (DBH).Type: GrantFiled: June 7, 1995Date of Patent: May 6, 1997Assignees: The Board of Supervisors of Louisana State and Agricultural and Mechanical College, Ergo Science IncorporatedInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5585347Abstract: Disclosed are methods for detecting abnormalities in prolactin daily rhythms. The methods involve comparing a prolactin profile of a vertebrate (including a human) subject being tested that has been compiled over a predetermined period to a predetermined standard prolactin profile for healthy subjects. The method also involves determining whether the vertebrate subject has an abnormal daily prolactin rhythm by ascertaining whether (i) at any point during waking hours the prolactin level of the subject being tested is greater than 1 SEM above the normal prolactin profile of said healthy subjects, and/or (ii) at any point during sleeptime the prolactin level of the subject being tested is at least 1 SEM lower than the normal prolactin profile of said healthy subjects. Also provided are methods for determining adjustments needed to an abnormal prolactin profile (or daily rhythm) to cause it to conform to the prolactin profile (or rhythm) of a healthy subject, and methods for effecting such adjustments.Type: GrantFiled: December 22, 1992Date of Patent: December 17, 1996Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana State Univerisity and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5565454Abstract: The present invention relates to methods for reducing stenosis after non-bypass invasive intervention and for ameloriating symptomatic chest pains following non-bypass invasive intervention comprising administering a daily amount of a dopamine-potentiating/prolactin-reducing compound at a predetermined time and continuing administration for a period of time at least sufficient to permit the vascular injury to heal.Type: GrantFiled: May 31, 1995Date of Patent: October 15, 1996Assignee: Ergo Science, IncorporatedInventor: Anthony H. Cincotta
-
Patent number: 5554623Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: May 26, 1994Date of Patent: September 10, 1996Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5344832Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 24, 1991Date of Patent: September 6, 1994Assignees: The Board of Supervisors of Louisiana University and Agricultural and Mechanical College, Ergo Science IncorporatedInventors: Anthony H. Cincotta, Albert H. Meier